Amylyx Pharmaceuticals, Inc. AMLX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$150.11M+31.4% | -$144.74M+52.0% | -$149.28M+42.5% | -$187.6M-13.1% | -$218.86M-208% | ||
| $467K-37.3% | $525K-41.9% | $577K-44.8% | $678K-39.8% | $745K-37.9% | ||
| $26.93M-10.1% | $27.65M-16.3% | $28M-21.9% | $27.73M-29.3% | $29.95M-24.3% | ||
| —— | —— | —— | —— | -$18.05M— | ||
| —— | —— | —— | —— | -$63.92M— | ||
| —— | —— | —— | —— | —— | ||
| $116K+112% | $169K+118% | -$395K— | -$395K— | -$936K— | ||
| -$913K+60.5% | -$1.19M+47.5% | -$1.77M+19.6% | -$2.32M-8.0% | -$2.31M-10.5% | ||
| -$120.4M+41.8% | -$123.34M+26.4% | -$154.45M-62.4% | -$165.65M-182% | -$206.98M-1,354% | ||
| —— | $138K— | $72K— | —— | —— | ||
| $147.91M— | $231.82M— | —— | —— | —— | ||
| —— | —— | —— | —— | $31.18M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $65.88M+2,401% | ||
| $766K+685% | $1.07M+345% | $431K+33.0% | $516K+1,222% | -$131K— | ||
| $168.91M+246% | $148.8M+252% | $147.32M+335% | -$21.74M— | -$115.62M— | ||
| $4.43M-50.6% | $5.53M-43.9% | $6.26M-41.1% | $7.32M-32.3% | $8.98M-6.7% | ||
| —— | —— | —— | —— | —— | ||
| $467K-37.3% | $525K-41.9% | $577K-44.8% | $678K-39.8% | $745K-37.9% | ||
| —— | $1.98M+392% | $1.31M— | $649.5K— | -$13.75K— | ||
| -$913K+60.5% | -$1.19M+47.5% | -$1.77M+19.6% | -$2.32M-8.0% | -$2.31M-10.5% | ||
| $1.52M-24.1% | $1.73M-11.5% | $1.94M+1.3% | $2.1M+11.8% | $2M+8.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $116K+112% | $169K+118% | -$395K— | -$395K— | -$936K— | ||
| —— | —— | —— | —— | —— | ||
| $10.27M+520% | $4.08M+91.2% | $3.85M+65.1% | $1.68M-40.5% | $1.66M-66.2% | ||
| $6.42M+374% | $3.36M+88.4% | $3.19M+71.2% | $1.44M-7.1% | $1.35M-40.3% | ||
| -$913K+60.5% | -$1.19M+47.5% | -$1.77M+19.6% | -$2.32M-8.0% | -$2.31M-10.5% | ||
| —— | -$123.48M+26.4% | -$154.52M-61.7% | -$165.68M-178% | -$207.08M-1,441% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Amylyx Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.